

Elie Haddad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8352387/publications.pdf>

Version: 2024-02-01

175
papers

10,836
citations

30070

54
h-index

34986

98
g-index

187
all docs

187
docs citations

187
times ranked

12469
citing authors

#	ARTICLE	IF	CITATIONS
1	Autologous humanized mouse models of iPSC-derived tumors enable characterization and modulation of cancer-immune cell interactions. <i>Cell Reports Methods</i> , 2022, 2, 100153.	2.9	9
2	Morbidity, Mortality, and Therapeutics in Combined Immunodeficiency: Data from the USIDNET Registry. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, , .	3.8	0
3	Stress Signal ULBP4, an NKG2D Ligand, Is Upregulated in Multiple Sclerosis and Shapes CD8 ⁺ T-Cell Behaviors. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	6
4	Granulocyte Transfusions in Patients with Chronic Granulomatous Disease Undergoing Hematopoietic Cell Transplantation or Gene Therapy. <i>Journal of Clinical Immunology</i> , 2022, 42, 1026-1035.	3.8	3
5	Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC. <i>Blood</i> , 2022, 140, 685-705.	1.4	26
6	Infections in Infants with SCID: Isolation, Infection Screening, and Prophylaxis in PIDTC Centers. <i>Journal of Clinical Immunology</i> , 2021, 41, 38-50.	3.8	36
7	Myogenic progenitor cells derived from human induced pluripotent stem cell are immune-tolerated in humanized mice. <i>Stem Cells Translational Medicine</i> , 2021, 10, 267-277.	3.3	5
8	French-language adaptation of the 16D and 17D Quality of Life measures and score description in two Canadian pediatric samples. <i>Health Psychology and Behavioral Medicine</i> , 2021, 9, 619-635.	1.8	4
9	Refractory pruritus responds to dupilumab in a patient with TTC7A mutation. <i>JAAD Case Reports</i> , 2021, 8, 9-12.	0.8	4
10	Successful management of familial hemophagocytic lymphohistiocytosis by the JAK 1/2 inhibitor ruxolitinib. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28954.	1.5	6
11	Intrabone infusion for allogeneic umbilical cord blood transplantation in children. <i>Bone Marrow Transplantation</i> , 2021, 56, 1937-1943.	2.4	1
12	Capturing T Lymphocytes'™ Dynamic Interactions With Human Neural Cells Using Time-Lapse Microscopy. <i>Frontiers in Immunology</i> , 2021, 12, 668483.	4.8	11
13	Multicentric Castleman disease revealing complete signal transducer and activator of transcription 1 deficiency treated by JAK1/2 inhibition. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3838-3840.e1.	3.8	4
14	Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 523-532.e8.	2.9	24
15	Case Report: Unmanipulated Matched Sibling Donor Hematopoietic Cell Transplantation In TBX1 Congenital Athymia: A Lifesaving Therapeutic Approach When Facing a Systemic Viral Infection. <i>Frontiers in Immunology</i> , 2021, 12, 721917.	4.8	2
16	Real-World Effectiveness of Common Treatment Strategies for Juvenile Idiopathic Arthritis: Results From a Canadian Cohort. <i>Arthritis Care and Research</i> , 2020, 72, 897-906.	3.4	14
17	Population pharmacokinetic analysis of weekly and biweekly IgPro20 (Hizentra®) dosing in patients with primary immunodeficiency. <i>International Immunopharmacology</i> , 2020, 81, 106005.	3.8	9
18	Pharmacokinetic Analysis of Weekly Versus Biweekly IgPro20 Dosing in Patients With Primary Immunodeficiency. <i>Clinical Pharmacology in Drug Development</i> , 2020, 9, 664-670.	1.6	3

#	ARTICLE	IF	CITATIONS
19	Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike. Cell Reports Medicine, 2020, 1, 100126.	6.5	200
20	Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activity. Seminars in Hematology, 2020, 57, 201-212.	3.4	17
21	HIV Infection and Persistence in Pulmonary Mucosal Double Negative T Cells In Vivo. Journal of Virology, 2020, 94, .	3.4	12
22	Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report. Blood, 2020, 135, 2094-2105.	1.4	87
23	Diagnostic assay to assist clinical decisions for unclassified severe combined immune deficiency. Blood Advances, 2020, 4, 2606-2610.	5.2	28
24	Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey. Frontiers in Immunology, 2020, 11, 239.	4.8	57
25	Neuroinflammatory Disease as an Isolated Manifestation of Hemophagocytic Lymphohistiocytosis. Journal of Clinical Immunology, 2020, 40, 901-916.	3.8	33
26	Common presentations and diagnostic approaches. , 2020, , 3-59.		1
27	Patients'™ NK cell stimulation with activated plasmacytoid dendritic cells increases dinutuximab-induced neuroblastoma killing. Cancer Immunology, Immunotherapy, 2020, 69, 1767-1779.	4.2	11
28	Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT. Journal of Clinical Immunology, 2019, 39, 653-667.	3.8	41
29	GX15'™070 (Obatoclax), a Bcl-2 family proteins inhibitor engenders apoptosis and pro-survival autophagy and increases Chemosensitivity in neuroblastoma. BMC Cancer, 2019, 19, 1018.	2.6	23
30	Natural Killer Cells Prevent the Formation of Teratomas Derived From Human Induced Pluripotent Stem Cells. Frontiers in Immunology, 2019, 10, 2580.	4.8	12
31	Tolerability of subcutaneous immunoglobulin 20%, Ig20Gly, in pediatric patients with primary immunodeficiencies. Immunotherapy, 2019, 11, 397-406.	2.0	7
32	The Tumor-Immune Response Is Not Compromised by Mesenchymal Stromal Cells in Humanized Mice. Journal of Immunology, 2019, 203, 2735-2745.	0.8	9
33	18F-Fluorodeoxyglucose positron emission tomography with computed tomography (FDG PET/CT) findings in children with encephalitis and comparison to conventional imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1309-1324.	6.4	24
34	Human models of NUP98-KDM5A megakaryocytic leukemia in mice contribute to uncovering new biomarkers and therapeutic vulnerabilities. Blood Advances, 2019, 3, 3307-3321.	5.2	23
35	Hematopoietic Stem Cell Transplantation for Severe Combined Immunodeficiency (SCID). Frontiers in Pediatrics, 2019, 7, 481.	1.9	22
36	Flt3L-Mediated Expansion of Plasmacytoid Dendritic Cells Suppresses HIV Infection in Humanized Mice. Cell Reports, 2019, 29, 2770-2782.e5.	6.4	23

#	ARTICLE	IF	CITATIONS
37	Efficient and Robust NK-Cell Transduction With Baboon Envelope Pseudotyped Lentivector. <i>Frontiers in Immunology</i> , 2019, 10, 2873.	4.8	84
38	The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018). <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 405-407.	2.9	64
39	Small-Fiber Neuropathy in a Pediatric Patient Following Anti-Tumor Necrosis Factor- α Therapy for Ulcerative Colitis. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2018, 66, e159-e161.	1.8	3
40	Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1036-1049.e5.	2.9	233
41	Health-Related Quality of Life in an Inception Cohort of Children With Juvenile Idiopathic Arthritis: A Longitudinal Analysis. <i>Arthritis Care and Research</i> , 2018, 70, 134-144.	3.4	50
42	Autosomal Dominant Hyper-IgE Syndrome in the USIDNET Registry. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 996-1001.	3.8	62
43	Trajectories of pain severity in juvenile idiopathic arthritis: results from the Research in Arthritis in Canadian Children Emphasizing Outcomes cohort. <i>Pain</i> , 2018, 159, 57-66.	4.2	29
44	Noncoding regions are the main source of targetable tumor-specific antigens. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	374
45	Rapamycin as an Adjunctive Therapy for NLRP4 Associated Macrophage Activation Syndrome. <i>Frontiers in Immunology</i> , 2018, 9, 2162.	4.8	26
46	SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery. <i>Blood</i> , 2018, 132, 1737-1749.	1.4	128
47	How i treat primary haemophagocytic lymphohistiocytosis. <i>British Journal of Haematology</i> , 2018, 182, 185-199.	2.5	42
48	B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation. <i>Blood</i> , 2018, 131, 2967-2977.	1.4	37
49	Conventional Dendritic Cells Impair Recovery after Myocardial Infarction. <i>Journal of Immunology</i> , 2018, 201, 1784-1798.	0.8	43
50	Humanized mouse model of Rasmussen's encephalitis supports the immune-mediated hypothesis. <i>Journal of Clinical Investigation</i> , 2018, 128, 2000-2009.	8.2	25
51	Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Severe Combined Immunodeficiency Patients: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 379-387.	2.0	49
52	Recommendations for Screening and Management of Late Effects in Patients with Severe Combined Immunodeficiency after Allogeneic Hematopoietic Cell Transplantation: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1229-1240.	2.0	44
53	Quality of Life, Treatment Beliefs, and Treatment Satisfaction in Children Treated for Primary Immunodeficiency with SCId. <i>Journal of Clinical Immunology</i> , 2017, 37, 496-504.	3.8	14
54	A Novel <i>PGM3</i> Mutation Is Associated With a Severe Phenotype of Bone Marrow Failure, Severe Combined Immunodeficiency, Skeletal Dysplasia, and Congenital Malformations. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1853-1859.	2.8	28

#	ARTICLE	IF	CITATIONS
55	Genotype, Phenotype and T Cell Counts at One Year Predict Survival and Long Term Immune Reconstitution after Transplantation in Severe Combined Immune Deficiency (SCID)â€”The Primary Immune Deficiency Treatment Consortium (PIDTC). <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S133-S134.	2.0	4
56	Amplification of Adipogenic Commitment by VSTM2A. <i>Cell Reports</i> , 2017, 18, 93-106.	6.4	18
57	Immune reconstitution and survival of 100 SCID patients postâ€”hematopoietic cell transplant: a PIDTC natural history study. <i>Blood</i> , 2017, 130, 2718-2727.	1.4	212
58	A protective role of IL-37 in cancer: a new hope for cancer patients. <i>Journal of Leukocyte Biology</i> , 2017, 101, 395-406.	3.3	46
59	Newborn screening for severe combined immunodeficiency: a primer for clinicians. <i>Cmaj</i> , 2017, 189, E1551-E1557.	2.0	22
60	Very Early-Onset Inflammatory Manifestations of X-Linked Chronic Granulomatous Disease. <i>Frontiers in Immunology</i> , 2017, 8, 1167.	4.8	23
61	Growth and weight gain in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort. <i>Pediatric Rheumatology</i> , 2017, 15, 68.	2.1	39
62	Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain. <i>Retrovirology</i> , 2017, 14, 47.	2.0	57
63	A Retrospective Study on Infusion-Related Reactions to Rituximab in a Heterogeneous Pediatric Population. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2017, 22, 369-374.	0.5	7
64	Human mesenchymal stromal cell-secreted lactate induces M2-macrophage differentiation by metabolic reprogramming. <i>Oncotarget</i> , 2016, 7, 30193-30210.	1.8	116
65	A Canadian Perspective on the Use of Immunoglobulin Therapy to Reduce Infectious Complications in Chronic Lymphocytic Leukemia. <i>Current Oncology</i> , 2016, 23, 42-51.	2.2	28
66	Rapid Infusion of Rituximab in a Heterogenous Pediatric Population. <i>Journal of Pediatric Hematology/Oncology</i> , 2016, 38, 83-85.	0.6	3
67	Signal transducer and activator of transcription 3. <i>Current Opinion in Hematology</i> , 2016, 23, 23-27.	2.5	56
68	20% subcutaneous immunoglobulin dosed biweekly for primary immunodeficiency. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 117, 93-94.	1.0	3
69	Primary Immune Deficiency Treatment Consortium (PIDTC) update. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 375-385.	2.9	33
70	Indoleamine 2,3-Dioxygenase-Expressing Aortic Plasmacytoid Dendritic Cells Protect against Atherosclerosis by Induction of Regulatory T Cells. <i>Cell Metabolism</i> , 2016, 23, 852-866.	16.2	92
71	Autophagy is associated with chemoresistance in neuroblastoma. <i>BMC Cancer</i> , 2016, 16, 891.	2.6	60
72	Poor T Cell Reconstitution at 100 Days after T Cell-Replete Hematopoietic Cell Transplantation (HCT) for SCID Is Associated with Later Risk of Death or Need for 2nd Transplant in the 6901 Prospective Study of the Pidtc. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S101-S102.	2.0	3

#	ARTICLE	IF	CITATIONS
73	The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1092-1098.	0.9	72
74	Variants in TRIM22 That Affect NOD2 Signaling Are Associated With Very-Early-Onset Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2016, 150, 1196-1207.	1.3	88
75	STAT3: too much may be worse than not enough!. <i>Blood</i> , 2015, 125, 583-584.	1.4	29
76	The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1854-1860.	0.9	192
77	Role of Natural Killer Cells in Intravenous Immunoglobulin-Induced Graft-versus-Host Disease Inhibition in NOD/LtSz-scidIL2rg ^{-/-} (NSG) Mice. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 821-828.	2.0	11
78	Early Hematopoietic Cell Transplant (HCT) Outcomes of Children with Severe Combined Immunodeficiency Disease (SCID): The First Seventy Four Patients of the Primary Immune Deficiency Treatment Consortium (PIDTC) Prospective Study 6901. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S289-S291.	2.0	2
79	Limited Sampling Strategies for Estimating Intravenous and Oral Cyclosporine Area Under the Curve in Pediatric Hematopoietic Stem Cell Transplantation. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 198-205.	2.0	4
80	Combined immunodeficiency in the United States and Kuwait: Comparison of patients' characteristics and molecular diagnosis. <i>Clinical Immunology</i> , 2015, 161, 170-173.	3.2	22
81	Subcutaneous Immunoglobulin Replacement Therapy with Hizentra® is Safe and Effective in Children Less Than 5 Years of Age. <i>Journal of Clinical Immunology</i> , 2015, 35, 558-565.	3.8	13
82	Intrabone Infusion of Umbilical Cord Blood Stem Cells to Improve Hematopoietic Recovery after Allogeneic Umbilical Cord Blood Transplantation in Children. <i>Blood</i> , 2015, 126, 4334-4334.	1.4	4
83	TRAIL-mediated killing of acute lymphoblastic leukemia by plasmacytoid dendritic cell-activated natural killer cells. <i>Oncotarget</i> , 2015, 6, 29440-29455.	1.8	21
84	Multiple Intestinal Atresia With Combined Immune Deficiency Related to TTC7A Defect Is a Multiorgan Pathology. <i>Medicine (United States)</i> , 2014, 93, e327.	1.0	35
85	Retrospective Study of 240 Patients with Severe Combined Immunodeficiency Transplanted from 2000-2009: A Report from the Primary Immune Deficiency Treatment Consortium of North America. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S24-S25.	2.0	1
86	Implication of different effector mechanisms by cord blood-derived and peripheral blood-derived cytokine-induced killer cells to kill precursor B acute lymphoblastic leukemia cell lines. <i>Cytotherapy</i> , 2014, 16, 845-856.	0.7	18
87	ICON: The Early Diagnosis of Congenital Immunodeficiencies. <i>Journal of Clinical Immunology</i> , 2014, 34, 398-424.	3.8	34
88	A systematic analysis of recombination activity and genotype-phenotype correlation in human recombination-activating gene 1 deficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 1099-1108.e12.	2.9	132
89	Primary Immune Deficiency Treatment Consortium (PIDTC) report. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 335-347.e11.	2.9	65
90	Development and characterization of a novel mouse model of Rasmussen's encephalitis. <i>Journal of Neuroimmunology</i> , 2014, 275, 118.	2.3	0

#	ARTICLE	IF	CITATIONS
91	Transplantation Outcomes for Severe Combined Immunodeficiency, 2000–2009. New England Journal of Medicine, 2014, 371, 434-446.	27.0	594
92	Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet, The, 2014, 383, 436-448.	13.7	322
93	Survey on retransplantation criteria for patients with severe combined immunodeficiency. Journal of Allergy and Clinical Immunology, 2014, 133, 597-599.	2.9	5
94	Retrospective Analysis Of The Clinical Utility Of Biweekly Dosing With High-Concentration Subcutaneous Immunoglobulin In 10 Patients With Primary Immunodeficiency. Journal of Allergy and Clinical Immunology, 2014, 133, AB184.	2.9	1
95	SClg vs. IVlg: let's give patients the choice!. Allergy, Asthma and Clinical Immunology, 2014, 10, A13.	2.0	1
96	Common Presentations and Diagnostic Approaches. , 2014, , 3-59.		2
97	Inflammatory Bowel Disease and T cell Lymphopenia in G6PC3 Deficiency. Journal of Clinical Immunology, 2013, 33, 520-525.	3.8	45
98	Cord Blood-Derived and Peripheral Blood-Derived Cytokine-Induced Killer Cells Are Sensitive to Fas-Mediated Apoptosis. Biology of Blood and Marrow Transplantation, 2013, 19, 1407-1411.	2.0	8
99	Pharmacoeconomic advantages of subcutaneous versus intravenous immunoglobulin treatment in a Canadian pediatric center. Journal of Allergy and Clinical Immunology, 2013, 131, 585-587.e3.	2.9	30
100	Severe Combined Immunodeficiency (SCID) in Canadian Children: A National Surveillance Study. Journal of Clinical Immunology, 2013, 33, 1310-1316.	3.8	26
101	Efficient BST2 antagonism by Vpu is critical for early HIV-1 dissemination in humanized mice. Retrovirology, 2013, 10, 128.	2.0	45
102	B-cell reconstitution for SCID: Should a conditioning regimen be used in SCID treatment?. Journal of Allergy and Clinical Immunology, 2013, 131, 994-1000.	2.9	83
103	A Soluble Granulocyte Colony Stimulating Factor Decoy Receptor as a Novel Tool to Increase Hematopoietic Cell Homing and Reconstitution in Mice. Stem Cells and Development, 2013, 22, 975-984.	2.1	3
104	Exome sequencing identifies mutations in the gene <i>TTC7A</i> in French-Canadian cases with hereditary multiple intestinal atresia. Journal of Medical Genetics, 2013, 50, 324-329.	3.2	119
105	Whole-Exome Sequencing Reveals a Rapid Change in the Frequency of Rare Functional Variants in a Founding Population of Humans. PLoS Genetics, 2013, 9, e1003815.	3.5	70
106	Short- and long-term outcome of linear morphea in children. British Journal of Dermatology, 2013, 169, 1265-1271.	1.5	62
107	Cord-Blood-Derived Mesenchymal Stromal Cells Downmodulate CD4 ⁺ T-Cell Activation by Inducing IL-10-Producing Th1 Cells. Stem Cells and Development, 2013, 22, 1063-1075.	2.1	36
108	Access to Biologic Therapies in Canada for Children with Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2012, 39, 1875-1879.	2.0	11

#	ARTICLE	IF	CITATIONS
109	Therapeutic Efficacy of Cord Blood-Derived Mesenchymal Stromal Cells for the Prevention of Acute Graft-Versus-Host Disease in a Xenogenic Mouse Model. <i>Stem Cells and Development</i> , 2012, 21, 1616-1626.	2.1	42
110	Use of immunoglobulins in the prevention of GvHD in a xenogeneic NOD/SCID/ $\beta^2\mu^{-}$ mouse model. <i>Bone Marrow Transplantation</i> , 2012, 47, 439-450.	2.4	45
111	CD133 expression is associated with poor outcome in neuroblastoma via chemoresistance mediated by the AKT pathway. <i>Histopathology</i> , 2012, 60, 1144-1155.	2.9	52
112	Human interferon-alpha increases the cytotoxic effect of CD56+cord blood-derived cytokine-induced killer cells on human B-acute lymphoblastic leukemia cell lines. <i>Cytotherapy</i> , 2012, 14, 1245-1257.	0.7	19
113	Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases. <i>Transfusion and Apheresis Science</i> , 2012, 46, 315-321.	1.0	26
114	Patient with X-linked phenotype of SCID, markedly skewed maternal X-inactivation, but normal common gamma chain (CD132) gene ORF sequence. <i>Allergy, Asthma and Clinical Immunology</i> , 2012, 8, .	2.0	0
115	Improved quality of life with home therapy with subcutaneous immunoglobulins for patients with secondary hypogammaglobulinaemia. <i>Allergy, Asthma and Clinical Immunology</i> , 2012, 8, .	2.0	0
116	Genotype analysis of tumor-initiating cells expressing CD133 in neuroblastoma. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 792-804.	2.8	17
117	Higher Doses of Subcutaneous IgG Reduce Resource Utilization in Patients with Primary Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2012, 32, 281-289.	3.8	26
118	Impact of storage temperature and processing delays on cord blood quality: discrepancy between functional in vitro and in vivo assays. <i>Transfusion</i> , 2012, 52, 2401-2405.	1.6	26
119	Abstract 2477: Autophagy is correlated with chemoresistance in neuroblastoma. , 2012, , .		0
120	X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. <i>Blood</i> , 2011, 117, 53-62.	1.4	268
121	Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. <i>Blood</i> , 2011, 118, 1675-1684.	1.4	296
122	Treatment costs associated with hospital-based intravenous immunoglobulin therapy compared to home-based subcutaneous immunoglobulin therapy in a cohort of paediatric patients with primary immunodeficiency. <i>Allergy, Asthma and Clinical Immunology</i> , 2011, 7, A25.	2.0	0
123	Abstract 4344: Membrane-type 1 matrix metalloproteinase-mediated pro-invasive properties of neuroblastoma initiating cells. , 2011, , .		7
124	The Use of Immunoglobulin Therapy for Patients With Primary Immune Deficiency: An Evidence-Based Practice Guideline. <i>Transfusion Medicine Reviews</i> , 2010, 24, S28-S50.	2.0	93
125	Development of a Novel Humanized Mouse Model of Rasmussen Encephalitis with Pathological and Clinical Characteristics of the Human Disease. <i>Clinical Immunology</i> , 2010, 135, S70-S71.	3.2	0
126	Immunomodulatory Effect of IVIG in a Humanized Mouse Model of Graft-versus-host Disease. <i>Clinical Immunology</i> , 2010, 135, S92.	3.2	0

#	ARTICLE	IF	CITATIONS
127	Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort. <i>Arthritis Care and Research</i> , 2010, 62, 527-536.	3.4	86
128	Ionizing radiation-induced long-term expression of senescence markers in mice is independent of p53 and immune status. <i>Aging Cell</i> , 2010, 9, 398-409.	6.7	131
129	Targeted gene addition to human mesenchymal stromal cells as a cell-based plasma-soluble protein delivery platform. <i>Cytotherapy</i> , 2010, 12, 394-399.	0.7	55
130	Predictors of early inactive disease in a juvenile idiopathic arthritis cohort: Results of a Canadian multicenter, prospective inception cohort study. <i>Arthritis and Rheumatism</i> , 2009, 61, 1077-1086.	6.7	68
131	Renal granuloma and immunoglobulin M-complex glomerulonephritis: a case of common variable immunodeficiency?. <i>Pediatric Nephrology</i> , 2009, 24, 601-604.	1.7	11
132	Varicella-Zoster Virus Disease Is More Frequent after Cord Blood Than after Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 867-871.	2.0	46
133	Chronic Active Gastritis in X-linked Lymphoproliferative Disease. <i>American Journal of Surgical Pathology</i> , 2008, 32, 323-328.	3.7	15
134	Immune Globulin for Patients with Primary Immune Deficiency: An Evidence Based Practice Guideline. <i>Blood</i> , 2008, 112, 4705-4705.	1.4	0
135	Presence of autoantibodies against tubular and uveal cells in a patient with tubulointerstitial nephritis and uveitis (TINU) syndrome. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 1452-1455.	0.7	50
136	A Humanized Mouse Model of Idiopathic Nephrotic Syndrome Suggests a Pathogenic Role for Immature Cells. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 2732-2739.	6.1	80
137	Evolution and Treatment of Childhood Chronic Inflammatory Polyneuropathy. <i>Pediatric Neurology</i> , 2007, 36, 88-94.	2.1	40
138	Childhood Systemic Lupus Erythematosus: New and Old Treatments. <i>Current Pediatric Reviews</i> , 2006, 2, 165-171.	0.8	0
139	Engagement of Transferrin Receptor by Polymeric IgA1: Evidence for a Positive Feedback Loop Involving Increased Receptor Expression and Mesangial Cell Proliferation in IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 2667-2676.	6.1	90
140	Initial presentation of childhood-onset systemic lupus erythematosus: A French multicenter study. <i>Journal of Pediatrics</i> , 2005, 146, 648-653.	1.8	206
141	Glycosylation and Size of IgA1 Are Essential for Interaction with Mesangial Transferrin Receptor in IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 622-634.	6.1	160
142	Impact of HLA matching on outcome of hematopoietic stem cell transplantation in children with inherited diseases: a single-center comparative analysis of genoidentical, haploidentical or unrelated donors. <i>Bone Marrow Transplantation</i> , 2004, 33, 1089-1095.	2.4	41
143	Encrusted cystitis and pyelitis in children: An unusual condition with potentially severe consequences. <i>Urology</i> , 2004, 64, 569-573.	1.0	27
144	RELATIONSHIP BETWEEN CD8+ T-CELL PHENOTYPE AND FUNCTION, EPSTEIN-BARR VIRUS LOAD, AND CLINICAL OUTCOME IN PEDIATRIC RENAL TRANSPLANT RECIPIENTS: A PROSPECTIVE STUDY1. <i>Transplantation</i> , 2004, 77, 1706-1713.	1.0	20

#	ARTICLE	IF	CITATIONS
145	Sudden blindness caused by anterior ischemic optic neuropathy in 5 children on continuous peritoneal dialysis1 1Published partially (case 3) in abstract form in Arch Ped 7:437, 2000, and in Pediatr Nephrol 16:C4, 2001.. American Journal of Kidney Diseases, 2003, 42, e19.1-e19.7.	1.9	28
146	Severe deficiency of the specific von Willebrand factor-cleaving protease (ADAMTS 13) activity in a subgroup of children with atypical hemolytic uremic syndrome. Journal of Pediatrics, 2003, 142, 310-317.	1.8	91
147	Enhanced Expression of the CD71 Mesangial IgA1 Receptor in Berger Disease and Henoch-Schönlein Nephritis: Association between CD71 Expression and IgA Deposits. Journal of the American Society of Nephrology: JASN, 2003, 14, 327-337.	6.1	88
148	Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-IL-2 receptor monoclonal antibody basiliximab. Transplantation, 2003, 76, 459-463.	1.0	77
149	Autoimmunity in Wiskott-Aldrich Syndrome: Risk Factors, Clinical Features, and Outcome in a Single-Center Cohort of 55 Patients. Pediatrics, 2003, 111, e622-e627.	2.1	294
150	A defect in hematopoietic stem cell migration explains the nonrandom X-chromosome inactivation in carriers of Wiskott-Aldrich syndrome. Blood, 2003, 102, 1282-1289.	1.4	77
151	Chronic intestinal graft-versus-host disease: clinical, histological and immunohistochemical analysis of 17 children. Bone Marrow Transplantation, 2002, 29, 223-230.	2.4	67
152	Pathogenic significance of IgA receptor interactions in IgA nephropathy. Trends in Molecular Medicine, 2002, 8, 464-468.	6.7	58
153	Clinical Quiz. Pediatric Nephrology, 2002, 17, 217-219.	1.7	3
154	Functional consequences of perforin gene mutations in 22 patients with familial haemophagocytic lymphohistiocytosis. British Journal of Haematology, 2002, 117, 965-972.	2.5	128
155	Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nature Genetics, 2002, 31, 166-170.	21.4	703
156	The interaction between Cdc42 and WASP is required for SDF-1-induced T-lymphocyte chemotaxis. Blood, 2001, 97, 33-38.	1.4	191
157	Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood, 2001, 97, 1590-1597.	1.4	122
158	The Thrombocytopenia of Wiskott Aldrich Syndrome Is Not Related to a Defect in Proplatelet Formation. Blood, 1999, 94, 509-518.	1.4	85
159	Long-Term Chimerism and B-Cell Function After Bone Marrow Transplantation in Patients With Severe Combined Immunodeficiency With B Cells: A Single-Center Study of 22 Patients. Blood, 1999, 94, 2923-2930.	1.4	119
160	Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: A retrospective survey of 31 patients. Journal of Pediatrics, 1999, 134, 589-596.	1.8	282
161	Influence of severe combined immunodeficiency phenotype on the outcome of HLA non-identical, T-cell-depleted bone marrow transplantationA retrospective European survey from the European Group for Bone Marrow Transplantation and the European Society for Immunodeficiency. Journal of Pediatrics, 1999, 134, 740-748.	1.8	111
162	The Thrombocytopenia of Wiskott Aldrich Syndrome Is Not Related to a Defect in Proplatelet Formation. Blood, 1999, 94, 509-518.	1.4	4

#	ARTICLE	IF	CITATIONS
163	Prevention of EBV-induced B-lymphoproliferative disorder by ex vivo marrow B-cell depletion in HLA-phenoidential or non-identical T-depleted bone marrow transplantation. British Journal of Haematology, 1998, 103, 543-551.	2.5	57
164	Invasive Pulmonary Infection Due to <i>Scedosporium apiospermum</i> in Two Children with Chronic Granulomatous Disease. Clinical Infectious Diseases, 1998, 27, 1437-1441.	5.8	135
165	Treatment of Familial Hemophagocytic Lymphohistiocytosis With Bone Marrow Transplantation From HLA Genetically Nonidentical Donors. Blood, 1997, 90, 4743-4748.	1.4	112
166	Frequency and Severity of Central Nervous System Lesions in Hemophagocytic Lymphohistiocytosis. Blood, 1997, 89, 794-800.	1.4	225
167	The majority of myeloid-antigen-positive (My +) childhood B-cell precursor acute lymphoblastic leukaemias express TEL-AML1 fusion transcripts. British Journal of Haematology, 1997, 99, 101-106.	2.5	63
168	Hepatic GVHD after HLA-haploidentical bone marrow transplantation in children with severe combined immunodeficiency: the effect of ursodeoxycholic acid. British Journal of Haematology, 1997, 96, 776-780.	2.5	11
169	Treatment of Familial Hemophagocytic Lymphohistiocytosis With Bone Marrow Transplantation From HLA Genetically Nonidentical Donors. Blood, 1997, 90, 4743-4748.	1.4	5
170	A child who was feverish for 2 years. Lancet, The, 1996, 348, 724.	13.7	3
171	Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: Report of five cases. Journal of Pediatrics, 1996, 129, 750-754.	1.8	215
172	Molecular detection of t(8;21)/AML1-ETO in AML M1/M2: correlation with cytogenetics, morphology and immunophenotype. British Journal of Haematology, 1996, 92, 855-865.	2.5	118
173	Correction of X-Linked Hyper-IgM Syndrome by Allogeneic Bone Marrow Transplantation. New England Journal of Medicine, 1995, 333, 426-429.	27.0	85
174	PREVENTION OF BONE MARROW AND CARDIAC GRAFT REJECTION IN AN H-2 HAPLOTYPE DISPARATE MOUSE COMBINATION BY AN ANTI-LFA-1 ANTIBODY. Transplantation, 1995, 59, 1576-1582.	1.0	31
175	PREVENTION OF BONE MARROW AND CARDIAC GRAFT REJECTION IN AN H-2 HAPLOTYPE DISPARATE MOUSE COMBINATION BY AN ANTI-LFA-1 ANTIBODY. Transplantation, 1995, 59, 1576-1582.	1.0	3